



ASX ANNOUNCEMENT

CLEANSING NOTICE UNDER SECTION 708A(5)(e) OF THE CORPORATIONS ACT

MELBOURNE, Australia 9 January 2023:

This cleansing notice is given by Lumos Diagnostic Holdings Limited (ASX:LDX) (**Company**) under section 708A(5)(e) of the *Corporations Act 2001* (Cth) (**Corporations Act**).

The Company advises that it has today issued 12,000,000 fully paid ordinary shares (**Shares**).

Pursuant to section 708A(5)(e) of the Corporations Act, the Company gives notice that:

- the Shares were issued without disclosure to investors under Part 6D.2 of the Corporations Act;
- the Company is providing this notice under paragraph (5)(e) of section 708A of the Corporations Act;
- as at the date of this notice, the Company has complied with:
 - the provisions of Chapter 2M of the Corporations Act, as they apply to the Company; and
 - section 674 and 674A of the Corporations Act; and
- as at the date of this notice, other than set out below, there is no information:
 - that has been excluded from a continuous disclosure notice in accordance with the ASX Listing Rules; and
 - that investors and their professional advisers would reasonably require for the purpose of making an informed assessment of:
 - the assets and liabilities, financial position and performance, profits and losses and prospects of the Company; or
 - the rights and liabilities attaching to the Shares.

This announcement has been approved by the Lumos Board of Directors

-Ends-

About Lumos Diagnostics

Lumos Diagnostics specialises in rapid, cost-effective, and complete point-of-care (POC) diagnostic test technology to help healthcare professionals more accurately diagnose and manage medical conditions. Lumos offers customised assay development and manufacturing services for POC tests and proprietary digital reader platforms. Lumos also directly develops, manufactures, and commercialises novel Lumos-branded POC tests that target infectious and inflammatory diseases.

For more information visit lumosdiagnostics.com

Media Contacts:

Matthew Wright – Australia
Director, NWR Communications
matt@nwrcommunications.com.au
+61 (0) 451 896 420

Investor Contact:

Matthijs Smith – Lumos Diagnostics
ir@lumosdiagnostics.com
+61 3 9087 1598

Company Registered Office:

Lumos Diagnostics Holdings Ltd
Level 4, 100 Albert Rd
South Melbourne, VIC 3205
+61 3 9087 1598